- KetaDASH will provide ketamine therapy for the treatment of mental health disorders
- KetaDASH is a managed service organization focused on the psychedelic sector with the mission of helping physicians streamline their practice operations, create new revenue opportunities, and achieve better patient outcomes.
- KetaDASH treatments will be conducted by a team of experienced physicians, therapists and nurses whom after an initial telemedicine visit will come to your home, office, or mobile location and provide a complete ketamine treatment experience, with a focus on safety, setting, comfort and efficacy of treatments.
- Treatment packages include initial telemedicine visit and follow up integration via telemedicine with ketamine experienced psychotherapists.
KetaDASH treatments will be conducted by a team of experienced nurses who will come to your home, office, or mobile location after initial telemedicine screening and provide a complete ketamine experience, with a focus on set and setting, with packages that include telemedicine integration with psychotherapists. This innovative service departs from in-clinic intravenous, treatment or unsupervised telehealth models to an at-home ketamine administration with telehealth and in-person medical supervision. A typical KetaDASH experience incorporates a prescribing doctor, a nurse for administration and monitoring, and psychotherapists for integration, all from the comfort of the patient’s home.
Ketamine therapy has turned out to be a life-changing alternative to antidepressants for many patients.
Ketamine is an FDA approved drug that has been used for over 50 years as a safe dissociative anesthetic that is now being studied as a treatment for major depression. In certain psychiatric conditions, such as treatment-resistant depression, anxiety, post-traumatic stress disorder and alcohol abuse, ketamine has shown very encouraging results.
Completing day-to-day activities are often challenging for patients with mental health disorders. For patients who suffer from depression and post-traumatic stress disorder, symptoms such as fatigue, social isolation, lack of motivation, and high levels of anxiety are frequent. Unfortunately, many of the patients who suffer from these mental health issues find it difficult to go to a physical clinic. By providing this treatment at the patient’s home, office, or mobile location, KetaDASH intends to broaden access to this important therapy.
KetaDASH is also available to ketamine clinics and qualified patients whose healthcare provider has prescribed it as a treatment. Qualified patients, doctors, and clinics are invited to visit KetaDash.com for more information.
About
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the
For Media and Investor Relations, please contact:
(866) 692-6847 Toll Free -
(404) 281-8556 Mobile and
Email: Ir@Ehave.com
LinkedIn: https://www.linkedin.com/in/davidkugelman
Phone: (623) 261-9046
Source:
2022 GlobeNewswire, Inc., source